Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 22538368)

1.

Angiopoietin like protein 4 expression is decreased in activated macrophages.

Feingold KR, Shigenaga JK, Cross AS, Moser A, Grunfeld C.

Biochem Biophys Res Commun. 2012 May 11;421(3):612-5. doi: 10.1016/j.bbrc.2012.04.055. Epub 2012 Apr 19.

PMID:
22538368
2.

The acute phase response stimulates the expression of angiopoietin like protein 4.

Lu B, Moser A, Shigenaga JK, Grunfeld C, Feingold KR.

Biochem Biophys Res Commun. 2010 Jan 22;391(4):1737-41. doi: 10.1016/j.bbrc.2009.12.145. Epub 2009 Dec 31.

PMID:
20043872
3.

Overexpression of angiopoietin-like protein 4 protects against atherosclerosis development.

Georgiadi A, Wang Y, Stienstra R, Tjeerdema N, Janssen A, Stalenhoef A, van der Vliet JA, de Roos A, Tamsma JT, Smit JW, Tan NS, Müller M, Rensen PC, Kersten S.

Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1529-37. doi: 10.1161/ATVBAHA.113.301698. Epub 2013 May 2.

5.

Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists.

Kazemi MR, McDonald CM, Shigenaga JK, Grunfeld C, Feingold KR.

Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1220-4. Epub 2005 Feb 10.

6.

Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome.

Strippoli R, Carvello F, Scianaro R, De Pasquale L, Vivarelli M, Petrini S, Bracci-Laudiero L, De Benedetti F.

Arthritis Rheum. 2012 May;64(5):1680-8. doi: 10.1002/art.33496.

7.

ADRP/ADFP and Mal1 expression are increased in macrophages treated with TLR agonists.

Feingold KR, Kazemi MR, Magra AL, McDonald CM, Chui LG, Shigenaga JK, Patzek SM, Chan ZW, Londos C, Grunfeld C.

Atherosclerosis. 2010 Mar;209(1):81-8. doi: 10.1016/j.atherosclerosis.2009.08.042. Epub 2009 Sep 2.

PMID:
19748622
8.

Chronic estradiol administration in vivo promotes the proinflammatory response of macrophages to TLR4 activation: involvement of the phosphatidylinositol 3-kinase pathway.

Calippe B, Douin-Echinard V, Laffargue M, Laurell H, Rana-Poussine V, Pipy B, Guéry JC, Bayard F, Arnal JF, Gourdy P.

J Immunol. 2008 Jun 15;180(12):7980-8.

9.

Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation.

Berlato C, Cassatella MA, Kinjyo I, Gatto L, Yoshimura A, Bazzoni F.

J Immunol. 2002 Jun 15;168(12):6404-11.

10.

Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa B signaling pathway components.

Dobrovolskaia MA, Medvedev AE, Thomas KE, Cuesta N, Toshchakov V, Ren T, Cody MJ, Michalek SM, Rice NR, Vogel SN.

J Immunol. 2003 Jan 1;170(1):508-19.

13.

Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor gamma and nuclear factor-kappaB in macrophages.

Necela BM, Su W, Thompson EA.

Immunology. 2008 Nov;125(3):344-58. doi: 10.1111/j.1365-2567.2008.02849.x. Epub 2008 Apr 18.

14.
15.
16.

Cutting edge: Toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor.

Hamerman JA, Ogasawara K, Lanier LL.

J Immunol. 2004 Feb 15;172(4):2001-5.

17.
18.

Toll-like receptor-mediated activation of B cells and macrophages by polysaccharide isolated from cell culture of Acanthopanax senticosus.

Han SB, Yoon YD, Ahn HJ, Lee HS, Lee CW, Yoon WK, Park SK, Kim HM.

Int Immunopharmacol. 2003 Sep;3(9):1301-12.

PMID:
12890428
20.

Melanoma inhibits macrophage activation by suppressing toll-like receptor 4 signaling.

Clarke JH, Cha JY, Walsh MD, Gamboni-Robertson F, Banerjee A, Reznikov LL, Dinarello CA, Harken AH, McCarter MD.

J Am Coll Surg. 2005 Sep;201(3):418-25.

PMID:
16125076
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk